Organization
Biogen, Inc.
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Biogen, Inc.
... Alpha Synuclein Market report incorporate AC Immune SA, AFFiRiS AG, BioArctic AB, Biogen Inc, Evotec AG, Genmab A/S, H. Lundbeck A/S, ICB International Inc, MedImmune ...
... Biogen (Nasdaq: BIIB) announced today the appointment of Jeffrey D. Capello as Executive Vice ...
... Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Evercore ISI ...
... Sclerosis (MS) treatment, but the big news is the pending approval of Roche/Biogen's Ocrevus, a powerful monoclonal antibody for relapsing and progressive MS patients that ...
... right to receive royalty revenue on FAMPYRA® (prolonged-release fampridine tablets) payable by Biogen, up to an agreed upon threshold of royalties. After this threshold is ...
... What puts a new drug launch in line for victory? Ask Gilead, Biogen and J&J To rank the meds, Trinity compiled details about R&D costs, ...
... a DMT switch. Consequently, APPs report not only significantly higher shares of Biogen's Tysabri and Sanofi Genzyme's Lemtrada, but also appear to be early adopters ...
... is today announcing that it has entered into a partnership agreement with Biogen to provide its LISA TRACKER kits for monitoring Flixabi® (an infliximab biosimilar). ...
... Helly Hansen, Smithfield Foods, Trucost, Danone, Interface, DSM, Walgreens, Ford, Rainforest Alliance, Biogen, Bechtel and AMD. Here are some of the featured speakers… Emerging Technologies, ...
... afford to remain on the sidelines in Alzheimer’s,” with fellow pharma giants Biogen, Merck, AstraZeneca and Lilly gearing up for readouts of pivotal trials over ...
... launches in history. Demand for SPINRAZA remains strong in the U.S., with Biogen reporting a 75% increase in the number of patients on therapy in ...
... six leading CLL treatments from Novartis, Gilead, Roche, Janssen Biotech, AbbVie and Biogen. It shows: How physicians rate each team overall, and for 12 key ...
... and advanced preclinical development stages. Aducanumab for Alzheimer's disease was partnered with Biogen and is currently in phase 3 clinical trials. BIIB054 for Parkinson's and ...
... for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license to all of its IP through the recent Settlement ...
... activities involving ALS drugs during 2012-17. The $784m strategic collaboration agreement between Biogen and Ionis to develop drugs for the treatment of neurological disorders was ...
... periods was primarily due to the $ 2.5 million milestone payment to Biogen under the license agreement, offset by decreases in professional services of $ ...
... CAMBRIDGE, Mass. - Biogen (NASDAQ: BIIB) will present new data from the long-term extension (LTE) of its ...
... X-linked retinoschisis (XLRS) product candidate as part of the company's collaboration with Biogen. To date, the company has completed enrollment of 12 patients in the ...
... CAMBRIDGE, Mass. & CARLSBAD, Calif. - Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that the end of ...
... of 100 US-based neurologists, the report covers 12 major therapies from Genzyme, Biogen, Bayer, Teva, Sanofi, Novartis, Roche, EMD Serono, and AbbVie/Biogen. Top Takeaways Barriers ...
... Sample of therapies covered Marketed Therapies Taltz (ixekizumab; Eli Lilly) Benepali (etanercept; Biogen/Samsung Bioepis) Remsima (infliximab; Celltrion/Napp/Mundipharma) Inflectra (infliximab; Pfizer/Celltrion) Cosentyx (secukinumab; Novartis) Otezla (apremilast; ...
... clinical trials at Molecular Insight Pharmaceuticals, Averion International Corporation, Bard Electrophysiology, and Biogen. Dan started in industry in data management at Quintiles. He also designed ...
... its in-house discovered BACE inhibitor, is being jointly developed by Eisai and Biogen Inc. (Headquarters: Massachusetts, United States, CEO: Michel Vounatsos, 'Biogen'). Two global Phase ...
... type of competitive entry that is fundamental to our innovative system." RELATED: Biogen, Samsung accuse AbbVie of evergreening Humira patents to block biosims For instance, ...
Want to see the full history of news or view news on a particular date? Upgrade to RelSci Professional now!
Start My Free Trial ➤